AngioDynamics, Inc. (NASDAQ:ANGO) Q1 2024 Earnings Call Transcript

Jim Clemmer: Yeah. Steve and I talk about that a lot, and we have conversations with our Board. I think today, given that the external market kind of disruptions and where things have gone, we want our investors to say, hey, we have a strong balance sheet. They want to take a time out for a second. Steve has given you guidance as to where we think our cash utilization will be this year. And if people look back a year ago after Q1, Steve gave the same guidance, we really hit that by the end of the year. So we’re really — we think we’re in a good position to utilize the cash we have. We do have a good strong balance sheet with cash. We’ll always talk about the investments that we’re looking at. And I’m sure at some point, it will be a good conversation around a buyback.

We believe there’s a disconnect in our value today, a strong disconnect. We’ll take a look at that, but we also want to share with investors who want to ensure that we have a stable balance sheet for a while. We get their view as well.

John Young: Thanks.

Jim Clemmer: Thanks, John.

Operator: I’d now like to turn the call back over to Mr. Clemmer for any closing remarks. Mr. Clemmer?

Jim Clemmer: Thank you, operator, and thanks again to all of our AngioDynamics employees. We are on a transformation here, changing our company to one that is highly differentiated by our science and technology and provides meaningful outcomes in patient wellness when our products are utilized. Thanks again, there are tremendous employees who enabled this to occur every day. I look forward to speaking with you at the end of our Q2. Thank you.

Operator: This will conclude today’s conference. You may now disconnect your lines at this time, and thank you for your participation.